Sanofi gets US FDA OK for talking injection device

Sanofi gets US FDA OK for talking injection device
Sanofi has received US FDA approval for an auto-injector that gives audio and visual cues to assist in the injection process.

The product - Auvi-Q (epinephrine injection, USP) – is used for the treatment of allergic reactions in people who are at risk for or have a history of anaphylaxis.

The idea is that under such life-threatening circumstances the device talks users or caregivers through each step of the injection process with audible and visual cues, including a five-second injection countdown and an alert light to signal when the injection is complete.

Sanofi licensed North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world.

Bryan Downey, Vice President, Auvi-Q, Sanofi US, said: “With this FDA approval, Auvi-Q will become the first-and-only epinephrine auto-injector that talks users through each step of the injection process,”

The French drugmaker licensed North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars